Information Provided By:
Fly News Breaks for October 15, 2018
ACRX
Oct 15, 2018 | 06:12 EDT
Jefferies analyst Roger Song upgraded AcelRx upgraded AcelRx Pharmaceuticals to Buy and raised his price target for the shares to $8 from $3. The analyst sees a high chance of approval for Dsuvia following Friday's positive FDA panel vote.
News For ACRX From the Last 2 Days
There are no results for your query ACRX